EUVIMEDScopri EUVIMED
CrossrefScheda informativa

Analysis of the Serum MicroRNA Expression Profiles in Patients With Type 2 Diabetic Nephropathy After Simultaneous Pancreas‐Kidney Transplantation

Luhao Liu, Chaoqun Yu, Peng Zhang, Rongxin Chen, Yuhe Guo, Jiali Fang, Junjie Ma, Guanghui Li, Zheng Chen

Organ Medicine · 2024

DOI: 10.1002/orm2.16 ↗
AbstractDati bibliografici

Abstract

ABSTRACT Background Simultaneous pancreas‐kidney (SPK) transplantation has become a standard therapy for end‐stage diabetic nephropathy patients. This study aims to investigate serum microRNA (miRNA) profiles in patients with type 2 diabetic nephropathy after SPK and explored the mechanism of insulin resistance induced by relevant miRNAs. Methods Patients with type 2 diabetic nephropathy were recruited at our organ transplantation center from June 2018 to March 2019. Six patients were randomly selected, and miRNA microarray analysis was performed to assess serum miRNA expression levels. Target genes were predicted, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted. Results The gene chip results revealed significant upregulation of miR‐320d, miR‐4701‐3p, and miR‐940 and significant downregulation of miR‐1229‐5p, miR‐125a‐3p, miR‐3614‐5p, miR‐6090, and miR‐6893‐5p. Target gene prediction and pathway analysis revealed that four miRNAs (miR‐125a‐3p, miR‐320d, miR‐940, and miR‐1229‐5p) form distinct signal regulatory networks. Conclusion Specific miRNA expression profiles are present in the serum of patients with diabetic nephropathy after simultaneous pancreas‐kidney transplantation. These specific miRNAs may be involved in the regulatory mechanism of restoring normoglycemia in diabetic nephropathy patients.

Conoscenze adatte al tuo lavoro.

Dall’inizio gratuito alla ricerca bibliografica personale, fino alla Research Suite completa.

Visualizza tariffe →

Sono inclusi tutti i testi integrali degli editori?

No. Citazioni, abstract e testi integrali sono contenuti diversi. La disponibilità dipende dalla fonte, dall’accesso aperto e dalle licenze esistenti. Un piano EUVIMED non sostituisce diritti aggiuntivi degli editori.

Visualizza tariffe →